Immunohistochemical Profiles of Brain Metastases from Breast Cancer

Overview

Journal J Neurooncol

Publisher Springer

Date 2008 Jul 24

PMID 18648908

Citations 20

Authors

Kan Yonemori

Koji Tsuta

Chikako Shimizu

Yutaka Hatanaka

Kaoru Hashizume

Makiko Ono

Yukihiro Nakanishi

Tadashi Hasegawa

Yasuji Miyakita

Yoshitaka Narita

Soichiro Shibui

Yasuhiro Fujiwara

Affiliations

Soon will be listed here.

Abstract

The aim of present study is to explore the immunohistochemical profiles of brain metastases from breast cancer. We retrospectively performed immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor type 2 (HER2/neu), and cytokeratin (CK) 5/6 in 29 patients with resected tumor specimens of brain metastases. Immunohistochemical staining for ER, PgR and HER2/neu was performed in 24 patients with primary tumors. The positive frequency of immunohistochemical profiles of ER, PgR, HER2/neu, and CK5/6, in the brain metastases were 13.8%, 6.9%, 37.9%, and 24.1%, respectively. The immunohistochemical profiles including ER, PgR, and HER2/neu of the primary tumor and the brain metastasis differed in seven patients (29.2%, N = 7/24). Interestingly, the biological characteristics of brain metastasis sometimes changed which were represented by immunohistochemical staining. Therefore, the changes in the biological features of breast cancer should be taken into account when developing treatment strategies, including new molecular-targeted drugs, for brain metastases.

Citing Articles

Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.

Dowling G, Keelan S, Cosgrove N, Daly G, Giblin K, Toomey S Breast Cancer Res Treat. 2024; 207(3):471-476.

PMID: 39090418 PMC: 11420314. DOI: 10.1007/s10549-024-07431-6.

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor.

Kim S, Lee Y, Lee S, Sung Y, Lee A, Kang J J Pathol Transl Med. 2023; 57(4):217-231.

PMID: 37460396 PMC: 10369139. DOI: 10.4132/jptm.2023.06.10.

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain.

Jiaxin C, Jinmei Z, Huiqiang Z, Xuexue W, Xiaobo W, Shaohua Z Front Neurol. 2022; 13:1002173.

PMID: 36353124 PMC: 9637832. DOI: 10.3389/fneur.2022.1002173.

Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance.

Kotecha R, Tonse R, Rubens M, McDermott M, Odia Y, Appel H Neurooncol Adv. 2021; 3(1):vdab010.

PMID: 33898990 PMC: 8055057. DOI: 10.1093/noajnl/vdab010.

Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives.

Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y Cancers (Basel). 2021; 13(5).

PMID: 33802424 PMC: 7959316. DOI: 10.3390/cancers13051078.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey J . Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006; 24(36):5658-63. DOI: 10.1200/JCO.2006.07.0250. View

Li B, Byskosh A, Molteni A, Duda R . Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol. 1994; 57(2):71-7. DOI: 10.1002/jso.2930570202. View

Mohsin S, Weiss H, Gutierrez M, Chamness G, Schiff R, DiGiovanna M . Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005; 23(11):2460-8. DOI: 10.1200/JCO.2005.00.661. View

Kamby C, Rasmussen B, Kristensen B . Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer. 1989; 60(2):252-7. PMC: 2247047. DOI: 10.1038/bjc.1989.264. View

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

Pertschuk L, Axiotis C, Feldman J, Kim Y, Karavattayhayyil S, Braithwaite L . Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems. Breast J. 2001; 5(6):369-374. DOI: 10.1046/j.1524-4741.1999.97088.x. View

Pestalozzi B, Brignoli S . Trastuzumab in CSF. J Clin Oncol. 2000; 18(11):2349-51. DOI: 10.1200/JCO.2000.18.11.2349. View

10.

Gong Y, Booser D, Sneige N . Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005; 103(9):1763-9. DOI: 10.1002/cncr.20987. View

11.

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

12.

Niehans G, Singleton T, Dykoski D, Kiang D . Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst. 1993; 85(15):1230-5. DOI: 10.1093/jnci/85.15.1230. View

13.

Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T . c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol. 2000; 73(1):17-20. DOI: 10.1002/(sici)1096-9098(200001)73:1<17::aid-jso5>3.0.co;2-2. View

14.

Hicks D, Short S, Prescott N, Tarr S, Coleman K, Yoder B . Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006; 30(9):1097-104. DOI: 10.1097/01.pas.0000213306.05811.b9. View

15.

Cleator S, Heller W, Coombes R . Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8(3):235-44. DOI: 10.1016/S1470-2045(07)70074-8. View

16.

Nielsen T, Hsu F, Jensen K, Cheang M, Karaca G, Hu Z . Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10(16):5367-74. DOI: 10.1158/1078-0432.CCR-04-0220. View

17.

Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax S . Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol. 2004; 203(4):918-26. DOI: 10.1002/path.1592. View

18.

Perren A, Weng L, Boag A, Ziebold U, Thakore K, Dahia P . Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999; 155(4):1253-60. PMC: 1867038. DOI: 10.1016/S0002-9440(10)65227-3. View

19.

Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V . HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res. 2006; 26(1B):647-53. View

20.

Lower E, Glass E, Blau R, Harman S . HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat. 2008; 113(2):301-6. DOI: 10.1007/s10549-008-9931-6. View